A new trading day began on Friday, with Spyre Therapeutics Inc. (NASDAQ: SYRE) stock price up 3.29% from the previous day of trading, before settling in for the closing price of $33.70. SYRE’s price has ranged from $8.43 to $47.97 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -49.91% over the past five years. Meanwhile, its annual earnings per share averaged 92.00%. With a float of $42.22 million, this company’s outstanding shares have now reached $50.92 million.
Let’s look at the performance matrix of the company that is accounted for 30 employees. In terms of profitability, gross margin is 7.49%, operating margin of -14987.72%, and the pretax margin is -17845.11%.
Spyre Therapeutics Inc. (SYRE) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Spyre Therapeutics Inc. is 10.86%, while institutional ownership is 94.66%. The most recent insider transaction that took place on Oct 25 ’24, was worth 235,900. Before that another transaction happened on Sep 03 ’24, when Company’s Chief Financial Officer sold 18,531 for $28.17, making the entire transaction worth $522,074. This insider now owns 116,422 shares in total.
Spyre Therapeutics Inc. (SYRE) Performance Highlights and Predictions
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -9.34 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.76 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 92.00% per share during the next fiscal year.
Spyre Therapeutics Inc. (NASDAQ: SYRE) Trading Performance Indicators
Here are Spyre Therapeutics Inc.’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 19.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -15.45, a number that is poised to hit -0.82 in the next quarter and is forecasted to reach -3.93 in one year’s time.
Technical Analysis of Spyre Therapeutics Inc. (SYRE)
Spyre Therapeutics Inc. (NASDAQ: SYRE) saw its 5-day average volume 0.39 million, a negative change from its year-to-date volume of 0.51 million. As of the previous 9 days, the stock’s Stochastic %D was 81.21%. Additionally, its Average True Range was 1.84.
During the past 100 days, Spyre Therapeutics Inc.’s (SYRE) raw stochastic average was set at 75.52%, which indicates a significant decrease from 82.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 39.70% in the past 14 days, which was lower than the 70.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $29.03, while its 200-day Moving Average is $30.49. Nevertheless, the first resistance level for the watch stands at $36.23 in the near term. At $37.64, the stock is likely to face the second major resistance level. The third major resistance level sits at $38.69. If the price goes on to break the first support level at $33.77, it is likely to go to the next support level at $32.72. Assuming the price breaks the second support level, the third support level stands at $31.31.
Spyre Therapeutics Inc. (NASDAQ: SYRE) Key Stats
With a market capitalization of 1.77 billion, the company has a total of 40,283K Shares Outstanding. Currently, annual sales are 890 K while annual income is -338,790 K. The company’s previous quarter sales were 0 K while its latest quarter income was -38,840 K.
